NASDAQ:ATOS Atossa Genetics (ATOS) Stock Price, News & Analysis $4.96 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.82 -0.14 (-2.90%) As of 05/22/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atossa Genetics Stock (NASDAQ:ATOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atossa Genetics alerts:Sign Up Key Stats Today's Range$4.84▼$5.1050-Day Range$4.71▼$6.1752-Week Range$3.76▼$19.35Volume28,196 shsAverage Volume51,449 shsMarket Capitalization$42.71 millionP/E RatioN/ADividend YieldN/APrice Target$36.33Consensus RatingHold Company Overview Atossa Genetics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies. The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence. In addition, Atossa has developed a proprietary intraductal microcatheter platform that enables direct delivery of therapeutic agents into the milk ducts, aiming to concentrate treatment at the tumor site while minimizing systemic side effects. Complementing these programs are diagnostic initiatives that utilize nipple aspirate fluid analysis to identify molecular changes associated with early-stage disease. Founded in 2009, Atossa Genetics has advanced its clinical programs through collaborations with leading academic and research institutions across North America. The company’s trials are conducted at major cancer centers and specialized breast health clinics, reflecting its commitment to rigorous scientific evaluation and patient-centric development. Under the leadership of CEO Steven C. Quay, MD, PhD, Atossa’s management team brings extensive experience in oncology drug development, regulatory affairs, and commercial strategy. The company continues to prioritize innovation in breast health by advancing its proprietary therapeutic and diagnostic platforms toward regulatory milestones and potential commercialization.AI Generated. May Contain Errors. Read More Atossa Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreATOS MarketRank™: Atossa Genetics scored higher than 51% of companies evaluated by MarketBeat, and ranked 499th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAtossa Genetics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAtossa Genetics has a consensus price target of $36.33, representing about 632.5% upside from its current price of $4.96.Amount of Analyst CoverageAtossa Genetics has only been the subject of 3 research reports in the past 90 days.Read more about Atossa Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atossa Genetics are expected to grow in the coming year, from ($4.41) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atossa Genetics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.35% of the float of Atossa Genetics has been sold short.Short Interest Ratio / Days to CoverAtossa Genetics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Atossa Genetics has recently decreased by 4.10%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment-0.74 News SentimentAtossa Genetics has a news sentiment score of -0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atossa Genetics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ATOS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows7 people have added Atossa Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by Insiders9.80% of the stock of Atossa Genetics is held by insiders.Percentage Held by Institutions12.74% of the stock of Atossa Genetics is held by institutions.Read more about Atossa Genetics' insider trading history. Receive ATOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atossa Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATOS Stock News HeadlinesAtossa Genetics' Endoxifen Gains Attention as Well-Tolerated Breast Cancer OptionMay 21, 2026 | americanbankingnews.comAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular DystrophyMay 20, 2026 | prnewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 25 at 1:00 AM | Brownstone Research (Ad)Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research TranscriptMay 19, 2026 | seekingalpha.comAtossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast CancerMay 14, 2026 | prnewswire.comAtossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 8, 2026 | prnewswire.comAtossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal WomenMay 6, 2026 | prnewswire.comATOS stock jumps 8% today – an FDA designation draws investor cheer for Atossa TherapeuticsMay 5, 2026 | msn.comSee More Headlines ATOS Stock Analysis - Frequently Asked Questions How have ATOS shares performed this year? Atossa Genetics' stock was trading at $8.85 at the beginning of 2026. Since then, ATOS shares have decreased by 44.0% and is now trading at $4.96. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc. (NASDAQ:ATOS) released its earnings results on Friday, May, 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by $0.12. When did Atossa Genetics' stock split? Atossa Genetics shares reverse split on Monday, February 2nd 2026.The 1-15 reverse split was announced on Monday, January 26th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Atossa Genetics IPO? Atossa Genetics (ATOS) raised $6 million in an IPO on Thursday, November 8th 2012. The company issued 1,200,000 shares at a price of $4.00-$6.00 per share. How do I buy shares of Atossa Genetics? Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atossa Genetics investors own include Zomedica (ZOM), AUO (AUOTY), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), Waste Connections (WCN), American Water Works (AWK) and The RMR Group (RMR). Company Calendar Last Earnings5/08/2026Today5/25/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ATOS's financial health is in the Red zone, according to TradeSmith. ATOS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATOS CIK1488039 Webatossatherapeutics.com Phone(206) 588-0256Fax206-430-1288Employees8Year Founded2009Price Target and Rating Average Price Target for Atossa Genetics$36.33 High Price Target$60.00 Low Price Target$24.00 Potential Upside/Downside+632.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-84.91% Return on Assets-72.36% Debt Debt-to-Equity RatioN/A Current Ratio4.92 Quick Ratio4.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.54 per share Price / Book1.40Miscellaneous Outstanding Shares8,610,000Free Float7,767,000Market Cap$42.71 million OptionableOptionable Beta1.25 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:ATOS) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
